ReviewNature reviews. Clinical oncology2020
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
5 registry-linked trialsOpen access · hybridAbstract readReview
In one paragraph
Review in Nature reviews. Clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 230 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
230citing papers in PubMed, 7 pooled it
18.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study
Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer
Molecular Profiling and Dynamic Changes of Circulating Tumor DNA in Unresectable Locally Advanced Non-small Cell Lung Cancer
Study on the Clinical Potential of Circulating Tumor DNA in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients Treated With Immunotherapy
ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study
Who cites it
230 citing papers in PubMed, 7 syntheses or guidelines pooled it, 359 citations in OpenAlex.
- Circulating tumor DNA in Non-Viral head and neck squamous cell Carcinoma: A systematic review and Meta-Analysis.Oral oncology · 2025Pooled it
- Research trends and hotspots of circulating tumor DNA in colorectal cancer: a bibliometric study.Frontiers in oncology · 2025Pooled it
- Efficacy and Safety of Anti-EGFR Therapy Rechallenge in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2024Pooled it
- Bibliometric analysis of global research trends and prospects on circulating tumor DNA in colorectal cancer.Frontiers in oncology · 2024Pooled it
- Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses.Frontiers in oncology · 2023Pooled it
- ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis.Annals of surgical oncology · 2022Pooled it
- Tumor-Free Circulating Tumor DNA in Node-Negative Rectal Cancers Undergoing Neoadjuvant Chemotherapy, Excision, and Observation in the Phase II NEO Trial (CO.28).JCO precision oncology · 2026Trial
- Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01).Cancer research communications · 2022Trial
- Trial
- Efficacy of circulating tumour DNA in guiding postoperative adjuvant chemotherapy for resectable colorectal cancer: A meta-analysis based on cohort studies.Oncology letters · 2026Article
- Molecular sampling limits of ctDNA detection in clinical plasma samples.The journal of liquid biopsy · 2026Article
- Current Evidence for Circulating Tumor DNA in Sarcoma: Challenges and Opportunities for Clinical Application.Journal of surgical oncology · 2026Review
- Circulating Tumor DNA for Minimal Residual Disease Detection and Recurrence Prediction in Upper Gastrointestinal Cancers: A Scoping Review.Journal of clinical medicine · 2026Review
- Circulating Tumor DNA-Guided Adjuvant and Post-Adjuvant Therapy in Resected Colorectal Cancer: From Molecular Residual Disease Detection to Proven Clinical Utility.Biomedicines · 2026Review
- MammaTrace - a tumor naïve cell-free DNA methylation test for minimal residual disease in breast cancer.NPJ precision oncology · 2026Article
- Plasma proteomics-based liquid biopsy for predicting efficacy of PD-1-based immunochemotherapy in advanced gastric cancer: a prospective cohort study.Molecular biomedicine · 2026Article
- Evaluation of ct-DNA and mutational status in liquid biopsy of patients with metastatic colorectal cancer.Oncology letters · 2026Article
- Colorectal Cancer Treatment Delay Thresholds and Metastasis Risk.JAMA network open · 2026Article
170 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors at 20 institutions in 3 countries.
Arvind Dasari *Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. adasari@mdanderson.org.ORCID http://orcid.org/0000-0001-5271-9744
Van K Morris *Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carmen J AllegraNational Cancer Institute, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-6402-2709
Chloe AtreyaUniversity of California at San Francisco Comprehensive Cancer Center, San Francisco, CA, USA.
Al B BensonDivision of Hematology/Oncology, Northwestern University, Chicago, IL, USA.
Patrick BolandDepartment of Medicine, Roswell Park Cancer Center, Buffalo, NY, USA.
Ki ChungDivision of Hematology & Oncology, Medical University of South Carolina, Charleston, SC, USA.
Mehmet S CopurCHI Health St Francis Cancer Treatment Center, Grand Island, NE, USA.
Ryan B CorcoranDepartment of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8173-5778
Dustin A DemingDivision of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Andrea DwyerUniversity of Colorado Cancer Center, Aurora, CO, USA.
Maximilian DiehnDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-2032-0581
Cathy EngDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thomas J GeorgeDepartment of Medicine, University of Florida Health Cancer Center, Gainesville, FL, USA.ORCID http://orcid.org/0000-0002-6249-9180
Marc J GollubDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rachel A GoodwinThe Ottawa Hospital Regional Cancer Centre, Ottawa, ON, Canada.
Stanley R HamiltonDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jaclyn F HechtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Howard HochsterRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.ORCID http://orcid.org/0000-0002-9893-1529
Theodore S HongDepartment of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MD, USA.
Federico InnocentiCenter for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, USA.
Atif IqbalSection of Colorectal Surgery, Division of Surgery, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9741-4119
Samuel A JacobsNational Adjuvant Surgical and Bowel Project Foundation/NRG Oncology, Pittsburgh, PA, USA.
Hagen F KenneckeDepartment of Oncology, Virginia Mason Cancer Institute, Seattle, WA, USA.
James J LeeDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, USA.
Christopher H LieuDivision of Medical Oncology, University of Colorado Cancer Center, Aurora, CO, USA.
Heinz-Josef LenzDepartment of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-2178-9568
O Wolf LindwasserCoordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-2414-547X
Clara MontagutHospital del Mar-Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra, Barcelona, Spain.
Bruno OdisioDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fang-Shu OuDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-1267-8735
Laura PorterPatient Advocate, NCI Colon Task Force, Boston, MA, USA.
Kanwal RaghavDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Deborah SchragDivision of Population Sciences, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Aaron J ScottDivision of Hematology and Oncology, Banner University of Arizona Cancer Center, Tucson, AZ, USA.ORCID http://orcid.org/0000-0002-0301-3072
Qian ShiDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
John H StricklerDivision of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0001-7579-1175
Alan VenookUniversity of California at San Francisco Comprehensive Cancer Center, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9749-6548
Rona YaegerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Greg YothersDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-7965-7333
Y Nancy YouDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5294-288X
Jason A ZellDepartment of Epidemiology, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA, USA.ORCID http://orcid.org/0000-0003-2661-904X
Scott KopetzDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9647-3416
The University of Texas MD Anderson Cancer Center · USMemorial Sloan Kettering Cancer Center · USMassachusetts General Hospital · USMayo Clinic · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of Colorado Cancer Center · USBaylor College of Medicine · USCHI Health St. Francis · USDana-Farber Cancer Institute · USDuke Medical Center · USMedical University of South Carolina · USNational Cancer Institute · USNational Institutes of Health · USNorthwestern University · USNRG Oncology · USOttawa Hospital · CAPatient Advocate Foundation · USRoswell Park Comprehensive Cancer Center · USRutgers, The State University of New Jersey · USStanford University · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MNCI National Clinical Trials Network - Lead Academic Participating SiteUG1CA233324 · NCI · UNIVERSITY OF COLORADO DENVER · PI ANTHONY D ELIAS · 2019 to 2026
$5.2MNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016672NCI NIH HHS UG1 CA233324
Abstract
An increasing number of studies are describing potential uses of circulating tumour DNA (ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area of research, the Colon and Rectal-Anal Task Forces of the United States National Cancer Institute convened a panel of multidisciplinary experts to summarize current data on the utility of ctDNA in the management of colorectal cancer and to provide guidance in promoting the efficient development and integration of this technology into clinical care. The panel focused on four key areas in which ctDNA has the potential to change clinical practice, including the detection of minimal residual disease, the management of patients with rectal cancer, monitoring responses to therapy, and tracking clonal dynamics in response to targeted therapies and other systemic treatments. The panel also provides general guidelines with relevance for ctDNA-related research efforts, irrespective of indication.
Indexed as
Biomarkers, TumorCirculating Tumor DNAColonColorectal NeoplasmsHumansLiquid BiopsyNational Cancer Institute (U.S.)Neoplasm, ResidualRectal NeoplasmsUnited StatesBiomarkers, TumorCirculating Tumor DNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05031975ClinicalTrials.gov
NCT05379907ClinicalTrials.gov
NCT05641870ClinicalTrials.gov
NCT06098560ClinicalTrials.gov
NCT06609551ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.